Life Sciences & MOB Investment: Resilience Amidst Headwinds

By Majid Radaei, RadCRE · · Industry Insights

Despite broader CRE turbulence, investment demand for life sciences and medical office buildings (MOBs) remains robust, driven by innovation and demographic shifts, with transactions such as Healthpeak's sale of $1.5 billion in MOBs underscoring market confidence.

Converging Forces Sustain Life Sciences and MOB Investment

In a commercial real estate landscape marked by fluctuating interest rates and re-pricing across many asset classes, the life sciences and medical office building (MOB) sectors continue to exhibit remarkable resilience and strong investor demand. These sectors are underpinned by durable macroeconomic trends, including an aging population, advancements in biotechnology, and the increasing decentralization of healthcare services. While overall transaction volumes across CRE have softened, these specialized asset classes are attracting significant capital allocations from institutional investors, private equity firms, and even sovereign wealth funds seeking stable, long-term returns.

Key Drivers & Recent Activity

The life sciences sector, encompassing lab space, R&D facilities, and biomanufacturing, is experiencing sustained growth fueled by record venture capital funding into biotech and pharmaceutical companies. This funding translates directly into demand for specialized real estate, particularly in established hubs like Boston-Cambridge, the San Francisco Bay Area, and San Diego. CBRE reported that venture capital funding for life sciences totaled $32.4 billion in 2023, influencing continued build-out and acquisition of purpose-built facilities. Large-scale transactions, such as Blackstone's $12.8 billion acquisition of BioMed Realty in 2020 (and subsequent expansion), highlight the institutional appetite for this specialized real estate.

Medical office buildings, similarly, benefit from an inelastic demand driver: healthcare. The shift towards outpatient care, driven by cost efficiencies and patient convenience, has bolstered the MOB market. Investors are drawn to the long lease terms, credit tenancy (often health systems), and recession-resistant nature of these assets. Recent significant activity includes Healthpeak Properties' strategic portfolio optimization, where they sold a $1.5 billion portfolio of MOBs to a joint venture between Kayne Anderson Real Estate and Remedy Medical Properties in late 2023, showcasing active capital recycling and robust liquidity for high-quality assets.

Current Market Dynamics and Performance

According to Green Street's Public Storage REIT outlook, specialized healthcare REITs focusing on MOBs and life sciences have historically outperformed during periods of economic uncertainty. Market data from CoStar indicates that vacancy rates in prime life sciences markets remain exceptionally low, often in the single digits, despite new supply. MOB cap rates, while experiencing some upward pressure due to higher financing costs, generally remain compressed compared to traditional office, typically ranging from 5.5% to 6.5% for core assets, reflecting their perceived stability and lower risk profile.

The cost of capital, however, is a notable factor. While base rates like SOFR hover around 4.31%, bridge loans for these specialized properties might range from SOFR + 300-600 bps, while stabilized CMBS transactions for prime MOBs could see spreads around T + 150-300 bps. RadCRE has observed that carefully structured deals with strong sponsorship and pre-leased space continue to secure competitive financing terms.

RadCRE Perspective

Majid Radaei, Founder of RAD Commercial Realty, notes, "The current investment landscape for life sciences and MOBs is a compelling study in market fundamentals overcoming broader economic headwinds. While we’ve seen considerable re-pricing in asset classes like traditional retail and some segments of multifamily due to higher borrowing costs and inflation, life sciences and MOBs have largely held their own. For our clients, we're keenly focused on identifying opportunities where demand is exceeding supply, particularly in emerging submarkets within established clusters. We're also advising on optimizing capital stacks for these deals. For instance, while senior debt costs have risen, the stability of income from these asset types often justifies preferred equity or mezzanine financing in the 12-18% range, allowing sponsors to bridge the equity gap and achieve target returns. The key isn't just to chase growth, but to understand the specific nuances of medical tenancy and lab build-out requirements, which is where specialized expertise becomes invaluable — both in underwriting with our RadCRE.ai platform and in sourcing the right capital partners."

Outlook

The long-term outlook for life sciences and MOB investments remains positive. Demographic shifts, including population growth and an aging demographic requiring more medical services, coupled with relentless innovation in the pharmaceutical and biotech sectors, will continue to drive demand for these specialized properties. As interest rates begin to stabilize or potentially recede, these sectors are poised for further growth, making them attractive targets for strategic capital deployment. RadCRE remains committed to advising clients on navigating the complexities and capturing opportunities within these dynamic markets, leveraging our deep expertise in specialized real estate sectors.

Tags: life sciences real estate, medical office buildings, CRE investment demand, healthcare real estate, RadCRE financing, capital markets

Sources: CoStar, CBRE Research, Green Street, Commercial Observer, Healthpeak Properties investor relations